Cholic acid
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Inborn Errors of Bile Acid Synthesis
Conditions
Inborn Errors of Bile Acid Synthesis
Trial Timeline
Apr 1, 2010 → Aug 1, 2010
NCT ID
NCT01115582About Cholic acid
Cholic acid is a phase 3 stage product being developed by Mirum Pharmaceuticals for Inborn Errors of Bile Acid Synthesis. The current trial status is completed. This product is registered under clinical trial identifier NCT01115582. Target conditions include Inborn Errors of Bile Acid Synthesis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01115582 | Phase 3 | Completed |
| NCT01438411 | Phase 3 | Completed |
Competing Products
8 competing products in Inborn Errors of Bile Acid Synthesis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ataluren | Sanofi | Phase 2 | 51 |
| mipomersen sodium | Ionis Pharmaceuticals | Phase 2 | 49 |
| Mipomersen Sodium | Ionis Pharmaceuticals | Phase 3 | 74 |
| mipomersen + Placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| mipomersen + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| MK0653, ezetimibe + Comparator: placebo | Organon | Phase 3 | 72 |
| MK0653, ezetimibe + Comparator: placebo | Organon | Phase 3 | 72 |
| MK0653, ezetimibe + Comparator: placebo | Organon | Phase 3 | 72 |